Introduction
============

*Campylobacter jejuni* is one of the most common pathogens causing acute gastroenteritis in humans worldwide. It is usually transmitted through the ingestion of contaminated water or through contact with infected foods. In general, the clinical symptoms of *Campylobacter* enteritis include diarrhea, abdominal pain and/or fever. In \<0.1% of the cases, *Campylobacter* infection leads to extra-intestinal complications like Guillain-Barré syndrome \[[@B1]\].

Most Campylobacter infections are limited to the gastrointestinal tract. Bacteremia or extra-intestinal infections are considered rare. However, several reports on *Campylobacter* bacteremia emphasize the importance of clinical suspicions of *Campylobacter* spp. due to their slow growth in culture media, and resistance against widely-used antibiotics, including cephalosporins. In this report, we elaborate on the case of a female patient with liver cirrhosis who suffered from *C. jejuni* bacteremia. In addition, we present a literature review of the *Campylobacter* bacteremia cases reported in Asian countries.

Case Report
===========

A 73-year-old woman with cryptogenic liver cirrhosis (Child-Pugh score 10, class C) was hospitalized due to drowsiness, which aggravated three days before her visit to the hospital. Her initial vital signs were: blood pressure, 120/80 mmHg; heart rate, 60 beats/min; respiratory rate, 20 breaths/min; and body temperature, 36.5°C. No specific abnormalities or symptoms of infection were detected on physical examination. Initial laboratory findings showed: white blood cell (WBC) count, 5,700/mm^3^ (neutrophil 60.2%); hemoglobin, 10.6 g/dL; platelet count, 56,000/mm^3^; sodium, 144 mmol/L; potassium, 4.1 mmol/L; blood urea nitrogen (BUN), 21.2 mg/dL; and creatinine, 0.79 mg/dL. However, a liver function test showed elevated levels of aspartate transaminase (328 IU/L), alanine transaminase (259 IU/L), and alkaline phosphatase (199 IU/L). The C-reactive protein level was found to be 5.62 mg/L (normal range: 0-5 mg/L). There were no acute lesions on brain magnetic resonance imaging and a chest radiograph revealed mild cardiomegaly.

On the second day of hospitalization, a fever of 38.3°C was recorded, accompanied by chills and diarrhea. Cefotaxime (3 g/day) was administered as an empirical antibiotic to treat gastrointestinal infection. Initial fecal leukocyte tests and stool cultures yielded negative results, but after four days, a Gram-negative rod appeared in the blood culture. The patient was relieved of fever and diarrhea after two days, and cefotaxime was continued for eight days. Finally, *C. jejuni* was isolated in the blood culture ([Fig. 1](#F1){ref-type="fig"}).

![Microscopic finding of culture growth of *Campylobacter jejuni* from the patient's blood sample.\
Multiple Gram-negative bacilli are observed (Magnification ⨯ 1,000).](ic-49-230-g001){#F1}

An antibiotic susceptibility test of the isolated *C. jejuni* was performed using the disk diffusion test, which is also called Kirby-Bauer antibiotic testing. The susceptibility was analyzed according to the epidemiological cut-off (ECOFF) values of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@B2]\]. The isolated *C. jejuni* was showen to be resistant to ciprofloxacin and tetracycline but susceptible to erythromycin. In ceftazidime (16 mm), imipenem (39 mm), and ertapenem (34 mm), relatively large zone diameters were observed; however, there is no established breakpoint of *Campylobacter* against these, according to the EUCAST ([Table 1](#T1){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}). The total duration of hospitalization of the patient was 12 days. On discharge, the antibiotic was changed to oral azithromycin (500 mg/day), to be had for a period of five days.

###### Antibiotic susceptibility of isolated *Campylobacter jejuni*: disk diffusion method standardized and checked by European Committee on Antimicrobial Susceptibility Testing (EUCAST)

![](ic-49-230-i001)

  Antibiotics     Measurement (mm)   Zone diameter breakpoint (mm)   
  --------------- ------------------ ------------------------------- ------
  Ciprofloxacin   6                  26                              26
  Erythromycin    29                 20                              20
  Tetracycline    11                 30                              30
  Ceftazidime     16                 ND                              ND　
  Imipenem        39                 ND　 　                         ND　
  Ertapenem       34                 ND　 　                         ND　

S, susceptible; R, resistant; ND, no data.

![Antibiotic susceptibility test for isolated *Campylobacter jejuni* by disk diffusion method.\
CIP, ciprofloxacin; TE, tetracyclin; E, erythromycin; ETP, ertapenem; IPM, imipenem; CAZ, ceftazidime.](ic-49-230-g002){#F2}

Discussion
==========

*Campylobacter* spp. are one of the major gastrointestinal pathogens. In the United States, 9% of all food-borne infections are caused by *Campylobacter* \[[@B3]\]. However, in South Korea, the involvement of *Campylobacter* in food-borne infections is considered to be low (2.5%, 2013) \[[@B4]\]. *Campylobacter* bacteremia is rare, but it should not be ignored. We presented the case of *C. jejuni* bacteremia in a patient with liver cirrhosis. She suffered from fever and diarrhea, but recovered with the administration of empirical antibiotics and supportive care. *Campylobacter* grows slowly in culture media; occasionally 72-96 hours are required for primary isolation from biological samples \[[@B5]\]. In this case, *C. jejuni* was isolated after 10 days of culture. Though *Campylobacter* bacteremia might resolve without antibiotic treatment in a normal host, it is important to know the local epidemiology of anti-microbial susceptibility of *Campylobacter* and to select appropriate empirical antibiotics to treat chronically ill patients with comorbidities.

The global burden of disease and epidemiologic characteristics of *Campylobacter* bacteremia in Asian countries were unknown. Thus, we reviewed the reported cases of *Campylobacter* bacteremia, published between 2000 and 2014 ([Table 2](#T2){ref-type="table"}) \[[@B1][@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18]\]. A total of 51 *Campylobacter* bacteremia cases were identified (Taiwan, 25; Japan, 16; Hong Kong, 8; Singapore, 1; Thailand, 1). A majority of the patients (49/51, 96.1%) suffered from underlying diseases such as hematologic malignancy, liver disease, renal disease, or cancer, all of which can cause the deterioration of host immunity. Most of the patients had a fever (35/48, 72.9%), but diarrhea (14/48, 29.2%) and abdominal pain (9/48, 18.8%) were rare.

###### Reported *Campylobacter* bacteremia cases in Asian countries during 2000-2014

![](ic-49-230-i002)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                  Study location   Number of patients   Underlying diseases               Clinical features   Subspecies (No.)        Antibiotic susceptibility (susceptible/tested)   Antibiotics used                                                                       Outcome
  ------------------------------------------- ---------------- -------------------- --------------------------------- ------------------- ----------------------- ------------------------------------------------ -------------------------------------------------------------------------------------- ----------------------------------------------
  Mori et al.(2014) \[[@B1]\]                 Japan            7                    Acute leukemia: 1\                Fever: 7\           *C. jejuni*             Gentamicin: (7/7)\                               Ceftriaxone+Levofloxacin: 1\                                                           Recovered: 5\
                                                                                    Malignant lymphoma: 1\            Vomiting: 3\                                Clarithromycin: (6/6)\                           Ciprofloxacin+Meropenem: 1\                                                            Unknown: 2
                                                                                    Liver cirrhosis and cancer: 2\    Diarrhea: 2                                 Erythromycin: (6/6)\                             Meropenem: 1\                                                                          
                                                                                    Chronic hepatitis: 1\                                                         Ciprofloxacin: (3/6)\                            Azithromycin: 1\                                                                       
                                                                                    None: 2                                                                       Levofloxacin: (3/6)                              Tosufloxacin: 1\                                                                       
                                                                                                                                                                                                                   None: 2                                                                                

  Yamagami et al.(2014) \[[@B6]\]             Japan            1                    XLA: 1                            Fever               *C. fetus*              Ceftriaxone: N/A\                                Meropenem                                                                              Recovered
                                                                                                                                                                  Erythromycin: N/A\                                                                                                                      
                                                                                                                                                                  Levofloxacin: N/A\                                                                                                                      
                                                                                                                                                                  Meropenem: S                                                                                                                            

  Suzuki et al.(2013) \[[@B7]\]               Japan            1                    Advanced bile duct cancer: 1      ND                  *C. showae*             ND                                               ND                                                                                     ND

  Morishita et al.(2013) \[[@B8]\]            Japan            1                    Lumbar pyogenic spondylitis: 1    ND                  *C. lari*               ND                                               Piperacillin/Tazobactam+Erythromycin+Trimethoprim/Sulfamethoxazole                     Recovered

  Liao et al.(2012) \[[@B9]\]                 Taiwan           24                   Renal insufficiency: 10\          Fever: 14\          *C. coli* (15)\         Ampicillin-Sulbactam: (18/24)\                   Cephalosporin: 13\                                                                     Recovered: 21\
                                                                                    Liver cirrhosis: 9\               Diarrhea: 8\        *C. fetus* (6)\         Cefotaxime: (0/24)\                              Fluoroquinolone: 5\                                                                    Mortality: 3
                                                                                    Malignancy: 8\                    Abdominal pain: 7   *C. jejuni* (3)         Ciprofloxacin: (8/24)\                           Amoxicillin/Clavulanate: 3\                                                            
                                                                                    Diabetes mellitus: 5\                                                         Levofloxacin: (9/24)\                            Macrolide: 2                                                                           
                                                                                    Heart failure: 2\                                                             Ertapenem: (12/24)\                                                                                                                     
                                                                                    Hypogammaglobulinemia: 1                                                      Meropenem: (24/24)\                                                                                                                     
                                                                                                                                                                  Erythromycin: (5/24)                                                                                                                    

  Abe et al.(2012) \[[@B10]\]                 Japan            1                    Pheochromocytoma: 1               Fever, Fatigue      *C. fetus*              ND                                               Meropenem→Ciprofloxacin                                                                Recovered

  Shimizu et al.(2012) \[[@B11]\]             Japan            2                    ESRD: 2                           Fever: 2\           *C. upsaliensis* (1)\   Ceftriaxone: (2/2)\                              Ceftriaxone+Gentamicin for *C. upsaliensis*\                                           Recovered: 2
                                                                                                                      Diarrhea: 2         *C. fetus* (1)          Gentamicin: (2/2)\                               Meropenem for *C. fetus*                                                               
                                                                                                                                                                  Erythromycin: (2/2)\                                                                                                                    
                                                                                                                                                                  Levofloxacin: (0/2)                                                                                                                     

  Lang et al.(2009) \[[@B12]\]                Taiwan           1                    ESRD: 1                           ND                  *C. jejuni*             ND                                               Ciprofloxacin                                                                          Recovered

  Okada et al.(2008) \[[@B13]\]               Japan            1                    XLA: 1                            Fever, Leg pain     *C. coli*               Cefotaxime: R\                                   Imipenem, Meropenem, Gentamicin, Ciprofloxacin, Minocycline, Azithromycin, Kanamycin   Recovered
                                                                                                                                                                  Gentamicin: S\                                                                                                                          
                                                                                                                                                                  Imipenem, Meropenem: S\                                                                                                                 
                                                                                                                                                                  Erythromycin: I\                                                                                                                        
                                                                                                                                                                  Ciprofloxacin: S                                                                                                                        

  Arai et al.(2007) \[[@B14]\]                Japan            1                    XLA: 1                            Fever, Arthritis    *C. coli*               Ceftazidime: S\                                  Ceftazidime→Minocycline\                                                               Recovered
                                                                                                                                                                  Erythromycin: R                                  Cefepime and Meropenem for relapse                                                     

  Jirapongsananuruk et al.(2006) \[[@B15]\]   Thailand         1                    XLA: 1                            Fever, Dyspnea      *C. lari*               Aminoglycoside: S\                               3^rd^ cephalosporin+aminoglycoside, Amoxicillin/Clavulanate                            Recovered
                                                                                                                                                                  Cefepime: S\                                                                                                                            
                                                                                                                                                                  1--3^rd^ cephalosporin: R\                                                                                                              
                                                                                                                                                                  Fluoroquinolone: R                                                                                                                      

  Teh et al.(2004) \[[@B16]\]                 Singapore        1                    Ovarian vein thrombosis: 1        Fever, Loin pain    *C. fetus*              Ampicillin: S\                                   Ceftriaxone→Clarithromycin                                                             Recovered
                                                                                                                                                                  Aminoglycoside: S                                                                                                                       

  Chuman et al.(2003) \[[@B17]\]              Japan            1                    Adult T cell leukemia: 1          Fever               *C. fetus*              ND                                               Cefoperazone/Sulbactam                                                                 Death after 1 month due to tumor progression

  Woo et al.(2002) \[[@B18]\]                 Hong Kong        8                    Liver cirrhosis: 4\               Fever: 6\           *C. fetus*              Ampicillin: (8/8)\                               Penicillin+Gentamicin: 2\                                                              Recovered: 6\
                                                                                    Hepatocellular carcinoma: 2\      Diarrhea: 2\                                Gentamicin: (8/8)\                               Ampicillin+Gentamicin: 1\                                                              Mortality: 2
                                                                                    Heart valve disease: 2\           Abdominal pain: 3                           Ciprofloxacin: (7/8)\                            Cefuroxime: 2\                                                                         
                                                                                    CKD: 1                                                                        Imipenem: (8/8)                                  Amoxicillin/Clavulanate: 2\                                                            
                                                                                                                                                                                                                   Ticarcillin/Clavulanate: 1                                                             

  Total                                       Japan : 16\      51                   Underlying disease present: 49\                       *C. fetus* (19)\                                                                                                                                                
                                              Hong Kong : 8\                        No underlying disease: 2                              *C. coli* (17)\                                                                                                                                                 
                                              Taiwan : 25\                                                                                *C. jejuni* (11)\                                                                                                                                               
                                              Singapore : 1\                                                                              Others (4)                                                                                                                                                      
                                              Thailand : 1                                                                                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N/A, not applicable; ND, no data; S, susceptible; I, intermediate; R, resistant; XLA, X-liked agammaglobulinemia; TB, tuberculosis; CKD, chronic kidney disease; ESRD, end-stage renal disease.

Microbiologically, *C. fetus* was found to be the most common strain (19/51, 37.3%) infecting these patients, followed by *C. coli* (17/51, 33.3%) and *C. jejuni* (11/51, 21.6%). *C. upsaliensis, C. showae,* and *C. lari* were also presented in several reports ([Table 2](#T2){ref-type="table"}) \[[@B1][@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18]\]. Thus, if extra-intestinal symptoms manifest in a patient and a Gram stain of the blood sample suggests the presence of a *Campylobacter* spp., *C. fetus, C. coli,* or *C. jejuni* infection should be considered.

Generally, third generation cephalosporins with or without aminoglycoside, macrolide monotherapy, or fluoroquinolone monotherapy were used as empirical treatments for *Campylobacter* infection in Asia; however, resistance to such antibiotics was noted ([Table 2](#T2){ref-type="table"})\[[@B1][@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18]\]. Antibiotic susceptibility for fluoroquinolones (ciprofloxacin: 19/40, 47.5%; levofloxacin: 13/33, 39.4%) and macrolides (erythromycin: 13/34, 38.2%) was generally low. In addition, *Campylobacter* species were not susceptible to third generation cephalosporins (3/29, 10.3%). However, they were consistently susceptible to carbapenem agents (imipenem: 9/9, 100%; meropenem: 26/26, 100%).

An optimal treatment regimen of *Campylobacter* infection is yet to be established. In this study, cefotaxime was administered as an empirical treatment, and this led to a favorable outcome in the patient. Although microbiological breakpoints of the disk susceptibility test for third generation cephalosporins against *Campylobacter* were not proposed by EUCAST, the National Committee for Clinical Laboratory Standards (NCCLS) guidelines present the breakpoint for cefotaxime as 23mm \[[@B19]\]. Antibiotic susceptibility of *C. jejuni* which was isolated in our patients, to ceftazidime showed a diameter as 16mm. Thus, third generation cephalosporin were considered to have an intermediate effect in such cases ([Table 1](#T1){ref-type="table"}). Definite breakpoints of *Campylobacter* for various antibiotics need to be established using the disk susceptibility test.

The rising antibiotic resistance of the *Campylobacter* spp. has been an issue. Since the late 1980s, fluoroquinolone resistance has been rising in several Asian and European countries, as well as in the United States. This could be attributed to local antibiotic usage in animal production. In South Korea, the antimicrobial susceptibility of the *Campylobacter* spp. to fluoroquinolone was found to be 79.5% (2006-2010). It was lower than erythromycin (87.2%) and gentamicin (92.3%), but higher than ampicillin (69.2%) and cephalothin (7.7%) \[[@B20]\]. The epidemiology of *Campylobacter* antibiotic susceptibility varies depending on the area and time. Therefore, further investigation on the local anti-microbial resistance trend of *Campylobacter* is required. Antibiotics should be selected carefully because global antibiotic resistance is gradually increasing and inappropriate antibiotic usage could have fatal outcomes.

In conclusion, *Campylobacter* infection, with or without bacteremia, should be considered if the patient has a fever or gastrointestinal symptoms. Cases of *Campylobacter* bacteremia in Asia reveal *C. fetus* to be the main pathogen. Fluoroquinolones and macrolides would be considered as empirical treatment agents based on the local epidemiology of antibiotic resistance. As for the third generation cephalosporins, microbiological breakpoints should be established in the disk diffusion test with respect to clinical outcomes.
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